1. Almost half of patients (47%) had either an objective response or had progression free survival for at least 6 ...
Click to read this study in The Lancet Oncology.
Click to read this study in JAMA Network Open.
Click to read this study in The Lancet Oncology.
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
Click here to read this study in JAMA Oncology.
Click to read this study in JAMA Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in European Journal of Cancer
1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!